journal article·2016-03Open access

Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment

João Conde, Nuria Oliva, Mariana Atilano, Hyun Seok Song, Natalie Artzi

Nature Materials· Volume 15· Issue 3

Abstract

The therapeutic potential of miRNA (miR) in cancer is limited by the lack of efficient delivery vehicles. Here, we show that a self-assembled dual-colour RNA-triple-helix structure comprising two miRNAs-a miR mimic (tumour suppressor miRNA) and an antagomiR (oncomiR inhibitor)-provides outstanding capability to synergistically abrogate tumours. Conjugation of RNA triple helices to dendrimers allows the formation of stable triplex nanoparticles, which form an RNA-triple-helix adhesive scaffold upon interaction with dextran aldehyde, the latter able to chemically interact and adhere to natural tissue amines in the tumour. We also show that the self-assembled RNA-triple-helix conjugates remain functional in vitro and in vivo, and that they lead to nearly 90% levels of tumour shrinkage two weeks post-gel implantation in a triple-negative breast cancer mouse model. Our findings suggest that the RNA-triple-helix hydrogels can be used as an efficient anticancer platform to locally modulate the expression of endogenous miRs in cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (50)

Show source-provided references
1. Kasinski, A. L. & Slack, F. J. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Rev. Cancer 11, 849–864 (2011).10.1038/nrc3166 ↗
2. Li, Z. & Rana, T. M. Therapeutic targeting of microRNAs: Current status and future challenges. Nature Rev. Drug Discov. 13, 622–638 (2014).10.1038/nrd4359 ↗
3. Yin, H. et al. Non-viral vectors for gene-based therapy. Nature Rev. Genet. 15, 541–555 (2014).10.1038/nrg3763 ↗
4. Conde, J., Edelman, E. R. & Artzi, N. Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: The jack-of-all-trades in cancer nanotheranostics? Adv. Drug Deliv. Rev. 81, 169–183 (2015).10.1016/j.addr.2014.09.003 ↗
5. Chen, Y. C., Gao, D. Y. & Huang, L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv. Drug Deliv. Rev. 81, 128–141 (2015).10.1016/j.addr.2014.05.009 ↗
6. Yin, P. T., Shah, B. P. & Lee, K. B. Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small 10, 4106–4112 (2014).10.1002/smll.201400963 ↗
7. Hao, L. L., Patel, P. C., Alhasan, A. H., Giljohann, D. A. & Mirkin, C. A. Nucleic acid–gold nanoparticle conjugates as mimics of microRNA. Small 7, 3158–3162 (2011).10.1002/smll.201101018 ↗
8. Endo-Takahashi, Y. et al. Systemic delivery of miR-126 by miRNA-loaded bubble liposomes for the treatment of hindlimb ischemia. Sci. Rep. 4, 3883 (2014).10.1038/srep03883 ↗
9. Chen, Y. C., Zhu, X. D., Zhang, X. J., Liu, B. & Huang, L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18, 1650–1656 (2010).10.1038/mt.2010.136 ↗
10. Anand, S. et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Med. 16, 909–914 (2010).10.1038/nm.2186 ↗
11. Wu, Y. et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 8, 1381–1389 (2011).10.1021/mp2002076 ↗
12. Mittal, A., Chitkara, D., Behrman, S. W. & Mahato, R. I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 35, 7077–7087 (2014).10.1016/j.biomaterials.2014.04.053 ↗
13. Cheng, C. J. et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107–110 (2015).10.1038/nature13905 ↗
14. Shu, D. et al. Systemic delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9, 9731–9740 (2015).10.1021/acsnano.5b02471 ↗
15. McKiernan, P. J., Cunningham, O., Greene, C. M. & Cryan, S. A. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int. J. Nanomed. 8, 3907–3915 (2013).
16. Cheng, C. J. & Saltzman, W. M. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol. Pharm. 9, 1481–1488 (2012).10.1021/mp300081s ↗
17. Guo, P. X. The emerging field of RNA nanotechnology. Nature Nanotech. 5, 833–842 (2010).10.1038/nnano.2010.231 ↗
18. Lee, J. B., Hong, J., Bonner, D. K., Poon, Z. & Hammond, P. T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nature Mater. 11, 316–322 (2012).10.1038/nmat3253 ↗
19. Mok, H., Lee, S. H., Park, J. W. & Park, T. G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nature Mater. 9, 272–278 (2010).10.1038/nmat2626 ↗
20. Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nature Nanotech. 7, 389–393 (2012).10.1038/nnano.2012.73 ↗
21. Haque, F. et al. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 7, 245–257 (2012).10.1016/j.nantod.2012.06.010 ↗
22. Shu, D., Shu, Y., Haque, F., Abdelmawla, S. & Guo, P. X. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nature Nanotech. 6, 658–667 (2011).10.1038/nnano.2011.105 ↗
23. Jendis, J., Strack, B. & Moelling, K. Inhibition of replication of drug-resistant HIV type 1 isolates by polypurine tract-specific oligodeoxynucleotide TFO A. AIDS Res. Hum. Retroviruses 14, 999–1005 (1998).10.1089/aid.1998.14.999 ↗
24. Moelling, K., Abels, S., Jendis, J., Matskevich, A. & Heinrich, J. Silencing of HIV by hairpin-loop-structured DNA oligonucleotide. FEBS Lett. 580, 3545–3550 (2006).10.1016/j.febslet.2006.05.033 ↗
25. Yoon, K., Hobbs, C. A., Walter, A. E. & Turner, D. H. Effect of a 5′-phosphate on the stability of triple helix. Nucleic Acids Res. 21, 601–606 (1993).10.1093/nar/21.3.601 ↗
26. Chan, P. P. & Glazer, P. M. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy. J. Mol. Med. 75, 267–282 (1997).10.1007/s001090050112 ↗
27. Holland, J. A. & Hoffman, D. W. Structural features and stability of an RNA triple helix in solution. Nucleic Acids Res. 24, 2841–2848 (1996).10.1093/nar/24.14.2841 ↗
28. Duca, M., Vekhoff, P., Oussedik, K., Halby, L. & Arimondo, P. B. The triple helix: 50 years later, the outcome. Nucleic Acids Res. 36, 5123–5138 (2008).10.1093/nar/gkn493 ↗
29. Foulkes, W. D., Smith, I. E. & Reis, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948 (2010).10.1056/NEJMra1001389 ↗
30. Nassirpour, R., Mehta, P. P., Baxi, S. M. & Yin, M. J. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 8, e62170 (2013).10.1371/journal.pone.0062170 ↗
31. Piovan, C. et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol. 6, 458–472 (2012).10.1016/j.molonc.2012.03.003 ↗
32. Conde, J., Oliva, N. & Artzi, N. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc. Natl Acad. Sci. USA 112, E1278–E1287 (2015).10.1073/pnas.1421229112 ↗
33. Oliva, N. et al. Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia. Sci. Transl. Med. 7, 272ra211 (2015).10.1126/scitranslmed.aaa1616 ↗
34. Schroeder, A., Levins, C. G., Cortez, C., Langer, R. & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. J. Int. Med. 267, 9–21 (2010).10.1111/j.1365-2796.2009.02189.x ↗
35. Francois, J. C. et al. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline copper chelate. Proc. Natl Acad. Sci. USA 86, 9702–9706 (1989).10.1073/pnas.86.24.9702 ↗
36. Chiou, C. C., Chen, S. W., Luo, J. D. & Chien, Y. T. Monitoring triplex DNA formation with fluorescence resonance energy transfer between a fluorophore-labeled probe and intercalating dyes. Anal. Biochem. 416, 1–7 (2011).10.1016/j.ab.2011.05.002 ↗
37. Wan, C. H., Cui, M., Song, F. R., Liu, Z. Q. & Liu, S. Y. Evaluation of effects of bivalent cations on the formation of purine-rich triple-helix DNA by ESI-FT-MS. J. Am. Soc. Mass Spectrom. 20, 1281–1286 (2009).10.1016/j.jasms.2009.02.026 ↗
38. Carlson, R. D., Olins, A. L. & Olins, D. E. Urea denaturation of chromatin periodic structure. Biochemistry 14, 3122–3125 (1975).10.1021/bi00685a013 ↗
39. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nature Rev. Mol. Cell Biol. 15, 509–524 (2014).10.1038/nrm3838 ↗
40. Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37–44 (2003).10.1038/nature01451 ↗
41. Conde, J. et al. 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi Therapeutics. Nano Today http://dx.doi.org/10.1016/j.nantod.2015.06.008 (in the press).10.1016/j.nantod.2015.06.008 ↗
42. Kitchens, K. M., Kolhatkar, I. B., Swaan, P. W. & Ghandehari, H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Ceco-2 cells. Mol. Pharm. 5, 364–369 (2008).10.1021/mp700089s ↗
43. Jones, A. T. Macropinocytosis: Searching for an endocytic identity and role in the uptake of cell penetrating peptides. J. Cell Mol. Med. 11, 670–684 (2007).10.1111/j.1582-4934.2007.00062.x ↗
44. Linares, J. et al. Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages. ACS Appl. Mater. Interfaces 6, 13697–13706 (2014).10.1021/am5031598 ↗
45. Iversen, T. G., Skotland, T. & Sandvig, K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6, 176–185 (2011).10.1016/j.nantod.2011.02.003 ↗
46. Segovia, N. et al. Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer. Adv. Healthc. Mater. 4, 271–280 (2015).10.1002/adhm.201400235 ↗
47. Sledge, G. W. et al. Past, present, and future challenges in breast cancer treatment. J. Clin. Oncol. 32, 1979–1986 (2014).10.1200/JCO.2014.55.4139 ↗
48. Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663–1671 (2008).10.1056/NEJMoa0707056 ↗
49. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).10.1056/NEJMoa072113 ↗
50. Oliva, N. et al. Natural tissue microenvironmental conditions modulate adhesive material performance. Langmuir 28, 15402–15409 (2012).10.1021/la303155p ↗